• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Labcorp’s Raised 2026 Outlook and Oncology Push Could Shape Labcorp Holdings (LH) Investors

    Simply Wall St·05/05/2026 22:32:32
    Listen to the news
    • In the first quarter of 2026, Labcorp Holdings Inc. reported revenue of US$3,537.6 million and net income of US$277.8 million, with basic earnings per share from continuing operations rising to US$3.37 year over year.
    • Alongside raising its full-year 2026 revenue outlook, Labcorp continued returning capital to shareholders through a long-running buyback program and expanded its oncology testing capabilities with nationwide access to an FDA-approved companion diagnostic for KEYTRUDA-based treatment in platinum-resistant ovarian cancer.
    • Next, we’ll examine how Labcorp’s raised 2026 revenue guidance reshapes the company’s investment narrative and future growth assumptions.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    Labcorp Holdings Investment Narrative Recap

    To own Labcorp, you need to believe in the value of its large-scale diagnostics network and biopharma lab services, and that it can manage reimbursement and regulatory pressures. The Q1 2026 beat and modestly higher revenue outlook support the near term earnings catalyst, but do not materially change the key risk around potential PAMA-driven pressure on Medicare reimbursement rates.

    The most relevant recent announcement is Labcorp’s nationwide rollout of the PD-L1 IHC 22C3 pharmDx companion diagnostic for KEYTRUDA-based treatment in platinum-resistant ovarian cancer. This adds another specialized oncology test to its menu, tying directly into the catalyst that new, higher value tests in areas like oncology can deepen Labcorp’s role with both clinicians and biopharma customers.

    Yet investors should be aware that potential changes to Medicare reimbursement under PAMA could still...

    Read the full narrative on Labcorp Holdings (it's free!)

    Labcorp Holdings' narrative projects $16.3 billion revenue and $1.3 billion earnings by 2029. This requires 4.9% yearly revenue growth and an earnings increase of about $0.4 billion from $941.5 million today.

    Uncover how Labcorp Holdings' forecasts yield a $310.06 fair value, a 21% upside to its current price.

    Exploring Other Perspectives

    LH 1-Year Stock Price Chart
    LH 1-Year Stock Price Chart

    Three members of the Simply Wall St Community currently estimate Labcorp’s fair value between US$260 and about US$528. You can weigh those varied views against the raised 2026 revenue guidance and consider how reimbursement risks might influence the company’s ability to turn new testing capabilities into sustained earnings power.

    Explore 3 other fair value estimates on Labcorp Holdings - why the stock might be worth just $260.00!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Curious About Other Options?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.